This Title All WIREs
How to cite this WIREs title:
WIREs Nanomed Nanobiotechnol
Impact Factor: 7.689

Assessing the barriers to image‐guided drug delivery

Full article on Wiley Online Library:   HTML PDF

Can't access this content? Tell your librarian.

Imaging has become a cornerstone for medical diagnosis and the guidance of patient management. A new field called image‐guided drug delivery (IGDD) now combines the vast potential of the radiological sciences with the delivery of treatment and promises to fulfill the vision of personalized medicine. Whether imaging is used to deliver focused energy to drug‐laden particles for enhanced, local drug release around tumors, or it is invoked in the context of nanoparticle‐based agents to quantify distinctive biomarkers that could risk stratify patients for improved targeted drug delivery efficiency, the overarching goal of IGDD is to use imaging to maximize effective therapy in diseased tissues and to minimize systemic drug exposure in order to reduce toxicities. Over the last several years, innumerable reports and reviews covering the gamut of IGDD technologies have been published, but inadequate attention has been directed toward identifying and addressing the barriers limiting clinical translation. In this consensus opinion, the opportunities and challenges impacting the clinical realization of IGDD‐based personalized medicine were discussed as a panel and recommendations were proffered to accelerate the field forward. WIREs Nanomed Nanobiotechnol 2014, 6:1–14. doi: 10.1002/wnan.1247 This article is categorized under: Therapeutic Approaches and Drug Discovery > Emerging Technologies Diagnostic Tools > In Vivo Nanodiagnostics and Imaging Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease

This WIREs title offers downloadable PowerPoint presentations of figures for non-profit, educational use, provided the content is not modified and full credit is given to the author and publication.

Download a PowerPoint presentation of all images

Potential paradigm for increasing the efficiency of ‘bench to the clinic’ translation of image‐guided drug delivery (IGDD) technology achieved by synergizing the creativity of academia under government or foundation support with the product development and marketing capability of industry. Small companies capitalized by venture capital or private funds may serve to convert academic technology into pharmaceutically suitable, commercially scalable technologies that are produced under GLP to conduct preclinical stability and safety and GMP to open an IND for initiating Phase 1 human clinical trials. Involvement of industry provides smooth transition into later‐phase clinical studies and the market. CMC, chemistry, manufacturing, and controls; IND, investigational new drug application; GLP, Good Laboratory Practices; GMP, Good Manufacturing Practices; NDA, New Drug Application; CMS, Center for Medicare and Medicaid Services.
[ Normal View | Magnified View ]

Related Articles

Imaging: An Interdisciplinary View
Nanotechnology and Cancer

Browse by Topic

Therapeutic Approaches and Drug Discovery > Nanomedicine for Oncologic Disease
Therapeutic Approaches and Drug Discovery > Emerging Technologies
Diagnostic Tools > In Vivo Nanodiagnostics and Imaging

Access to this WIREs title is by subscription only.

Recommend to Your
Librarian Now!

The latest WIREs articles in your inbox

Sign Up for Article Alerts